GCS-100

Here's a look at the top tickers trending on StockTwits.com. La Jolla Pharmaceutical: Successful Phase 2 trial results Last night, La Jolla Pharmaceutical (NASDAQ: LJPC) reported that its Phase 2 trial of its GCS-100 chronic kidney disease drug “"met its primary efficacy endpoint of a...